AMLX - Company ID 0001658551
The table below shows Amylyx Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $0.00 | $0.00 | $416.00K | -$1.02M |
| Cost of revenue | - | $0.00 | $0.00 | $0.00 | $0.00 | $8.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | $27.61M | $19.86M | $27.22M | $22.12M | $21.24M | $23.35M |
Amylyx Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $87.37M in fiscal 2024. Over the 5 fiscal years shown, annual revenue declined from $285.00K (FY 2021) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $16.17M |
| $16.17M |
| $15.64M |
| $15.68M |
| $17.83M |
| $21.65M |
| Operating income | -$43.78M | -$36.03M | -$42.86M | -$37.80M | -$75.66M | -$76.29M |
| Income tax | - | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$41.28M | -$34.39M | -$41.44M | -$35.91M | -$72.70M | -$72.70M |
| EPS (diluted) | -$0.37 | -$0.37 | -$0.46 | -$0.42 | -$1.07 | -$1.07 |